Posts classified under: REMAP-CAP / COVID

News + Announcements

Global platform study presents results to guide care of severely ill patients with COVID-19 using routinely available drugs – simvastatin and Vitamin C

October 25, 2023  |  BUSINESSWIRE

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

May 19, 2022  |  BUSINESSWIRE

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

August 4, 2021  |  NEJM

GCAR Announces Discontinued Evaluation of Apremilast in REMAP-COVID

July 12, 2021  |  BUSINESSWIRE

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

February 25, 2021  |  NEJM

Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations

January 28, 2021  |  BIOMED CENTRAL

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

January 22, 2021  |  NATIONAL INSTITUTES OF HEALTH

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

October 26, 2020  |  BUSINESSWIRE

Corticosteroids Improve Survival in Critically Ill COVID-19 Patients

September 2, 2020  |  EUREKALERT

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

September 2, 2020  |  JAMA

Steroids Can Be Lifesaving for Covid-19 Patients, Scientists Report

September 2, 2020  |  NEW YORK TIMES

REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID

June 30, 2020  |  BUSINESSWIRE

International trial uses AI to rapidly identify optimal Covid-19 treatments

April 9, 2020  |  STAT